A revolutionary treatment for major depressive disorder (MDD), repetitive Transcranial Magnetic Stimulation (rTMS) can be successful where pharmaceutical treatment has failed.

About rTMS Therapy
Repetitive Transcranial Magnetic Stimulation (rTMS) is a treatment for depression that is revolutionizing the field of clinical psychiatry. Neuro-imaging techniques have shown that people suffering from MDD commonly display insufficient glucose metabolism levels, lower blood flow in the left dorsolateral pre-frontal cortex (DLPFC) and heightened activity in the limbic system.

During the treatment of depression, rTMS directly stimulates the DLPFC (an area located a few inches above the temple beneath the skull). This area is highly interconnected with limbic structures which also play an important role in regulating mood.

Key Benefits Of rTMS Therapy
An effective treatment for drug resistant depression
Safe, non-invasive therapy
No systemic side effects
Treated as an outpatient setting
Designed and built by Magstim, pioneers of rTMS technology with over 25 years experience, and a pedigree in reliability
Proven Efficacy Without Systemic Side Effects
rTMS is a completely non-invasive way to stimulate nerve cells in areas of the brain. It is used by healthcare professionals to treat a wide range of brain and nerve related disorders.  It has become an effective treatment for clinical depression, especially when other therapies have failed.  Over 80 trials of rTMS for MDD have been conducted in addition to 4 large multicentre trials. All have found significant amelioration of conditions following 6 weeks of daily prefrontal rTMS. There have been over a dozen meta analyses of the literature which confirm these findings. As the pioneer of Transcranial Magnetic Stimulation, Magstim is renowned as a world leader supplying rTMS products for diagnosis, research and therapy. In psychiatric therapy our simulators are used in the successful treatment of MDD.
Response Rates

A multisite, naturalistic, observational study of 307 patients, who had an average failure rate of 2.5 adequate medication trials, received an average of 28.3 rTMS therapy sessions over an average of 42 days. This study showed that 58% of patients responded positively to rTMS therapy and 37.1% of patients went into remission. [1]

MDD is one of the modern world’s most common and disabling medical illnesses. The “World Health Organization” estimates that depression will be the leading cause of disease burden globally by 2030. The global burden of MDD is presenting a huge challenge to clinical practitioners as increasing numbers of patients are turning to rTMS as a fast, effective and painless alternative to therapy, drugs and Electro Cerebral T.

Is rTMS Right For Me?

rTMS treatment has gained FDA clearance in the USA and has shown efficacy in drug resistant depression patients. We recommend that you should always consult with your doctor, psychiatrist, qualified healthcare professional, or a medical staff member.